MTUS1 and breast carcinoma: In conclusion, studies conducted over the past ten years with the aim to depict the expression and function of ATIP3 in breast cancer have successfully pointed out this protein as a robust prognostic biomarker of patient survival and a strong predictive biomarker for resistance to taxane-based chemotherapy.